DAVID J RIDLEY
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
- Where
- EAGAN, MN
- NPI
- 1659396000
- Received
- $28,065 in 65 records, 2019 to 2025 ($26,295 general, $1,769 research)
- As principal investigator
- $1,179,970 of research payments to others in 155 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 16 | $1,812 |
| 2024 | General payment | 5 | $371 |
| 2023 | General payment | 2 | $49 |
| 2022 | General payment | 7 | $7,334 |
| 2021 | General payment | 6 | $4,999 |
| 2020 | General payment | 1 | $1,616 |
| 2020 | Research payment | 7 | $1,769 |
| 2019 | General payment | 21 | $10,112 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 15 | $11,292 | 2019–2024 |
| Gilead Sciences, Inc. | 14 | $6,414 | 2019–2020 |
| Amgen Inc. | 4 | $5,432 | 2022–2025 |
| Janssen Research & Development, LLC | 11 | $1,731 | 2025 |
| Fresenius Kabi USA, LLC | 1 | $1,560 | 2022 |
| Janssen Biotech, Inc. | 6 | $816 | 2019–2025 |
| Janssen Scientific Affairs, LLC | 3 | $408 | 2022–2024 |
| ABBVIE INC. | 2 | $255 | 2022–2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $42 | 2022–2023 |
| Horizon Therapeutics plc | 2 | $41 | 2019–2023 |
| PFIZER INC. | 1 | $14 | 2021 |
| Daiichi Sankyo Inc. | 1 | $14 | 2019 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 | 2022 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 | 2021 |
| Genentech USA, Inc. | 1 | $13 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 7 | $16,366 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $5,400 |
| Travel and Lodging | 11 | $2,809 |
| Research payment | 7 | $1,769 |
| Food and Beverage | 37 | $1,480 |
| Grant | 1 | $239 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-10-30 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-04-24 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2025 | |
| 2025-04-22 | Janssen Biotech, Inc. | $13 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-04-15 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-04-02 | Janssen Biotech, Inc. | $19 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-01-25 | Janssen Research & Development, LLC | $224 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-25 | Janssen Research & Development, LLC | $64 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-25 | Janssen Research & Development, LLC | $9 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-24 | Janssen Research & Development, LLC | $236 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-24 | Janssen Research & Development, LLC | $137 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-24 | Janssen Research & Development, LLC | $54 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-24 | Janssen Research & Development, LLC | $9 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-23 | Janssen Research & Development, LLC | $450 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-23 | Janssen Research & Development, LLC | $236 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-23 | Janssen Research & Development, LLC | $234 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-23 | Janssen Research & Development, LLC | $75 | Food and Beverage | In-kind items and services | 2025 | ||
| 2024-06-21 | Janssen Biotech, Inc. | $12 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-06-14 | E.R. Squibb & Sons, L.L.C. | $42 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-06-12 | Janssen Scientific Affairs, LLC | $153 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-06-12 | Janssen Scientific Affairs, LLC | $150 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-03-27 | Genentech USA, Inc. | $13 | Food and Beverage | In-kind items and services | Actemra Biological, Immunology | 2024 | |
| 2023-07-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | CYLTEZO Drug, CNS | 2023 | |
| 2023-06-28 | Horizon Therapeutics plc | $21 | Food and Beverage | In-kind items and services | KRYSTEXXA Biological, KRYSTEXXA | 2023 | |
| 2022-12-12 | Fresenius Kabi USA, LLC | $1,560 | Consulting Fee | Cash or cash equivalent | Biological | 2022 | |
| 2022-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2022 | |
| 2022-11-14 | ABBVIE INC. | $239 | Grant | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2022 | |
| 2022-07-08 | Janssen Scientific Affairs, LLC | $105 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2022 | |
| 2022-06-24 | Amgen Inc. | $3,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Otezla Drug, Inflammation | 2022 | |
| 2022-06-24 | Amgen Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Otezla Drug, Inflammation | 2022 | |
| 2022-03-25 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | 2022 | |
| 2021-08-11 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | ORENCIA Biological, Immunology | 2021 | |
| 2021-07-20 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | INFLECTRA Biological, INFLAMMATION | 2021 | |
| 2021-07-07 | Janssen Biotech, Inc. | $750 | Consulting Fee | Cash or cash equivalent | STELARA Biological, Immunology | 2021 | |
| 2021-05-19 | E.R. Squibb & Sons, L.L.C. | $1,800 | Consulting Fee | Cash or cash equivalent | ORENCIA Biological, Immunology | 2021 | |
| 2021-02-16 | Actelion Pharmaceuticals US, Inc. | $14 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2021 | |
| 2021-02-05 | E.R. Squibb & Sons, L.L.C. | $2,400 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2020-09-03 | E.R. Squibb & Sons, L.L.C. | $1,616 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-01-30 | Gilead Sciences, Inc. | $834 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2020 | |
| 2020-01-30 | Gilead Sciences, Inc. | $543 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2020 | |
| 2020-01-30 | Gilead Sciences, Inc. | $125 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2020 | |
| 2020-01-30 | Gilead Sciences, Inc. | $125 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2020 | |
| 2020-01-30 | Gilead Sciences, Inc. | $50 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2020 | |
| 2020-01-30 | Gilead Sciences, Inc. | $50 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2020 | |
| 2020-01-30 | Gilead Sciences, Inc. | $41 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2020 | |
| 2019-12-18 | Gilead Sciences, Inc. | $3,840 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-12-13 | Gilead Sciences, Inc. | $44 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-12-13 | Gilead Sciences, Inc. | $31 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-12-13 | Gilead Sciences, Inc. | $7 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-12-12 | Gilead Sciences, Inc. | $428 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-12-12 | Gilead Sciences, Inc. | $179 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-12-12 | Gilead Sciences, Inc. | $113 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-10-16 | Daiichi Sankyo Inc. | $14 | Food and Beverage | In-kind items and services | Turalio Drug, Oncology | 2019 | |
| 2019-05-24 | E.R. Squibb & Sons, L.L.C. | $4,400 | Consulting Fee | Cash or cash equivalent | ORENCIA Biological, Immunology | 2019 | |
| 2019-05-20 | Horizon Therapeutics plc | $19 | Food and Beverage | In-kind items and services | KRYSTEXXA Biological, KRYSTEXXA | 2019 | |
| 2019-04-26 | E.R. Squibb & Sons, L.L.C. | $57 | Food and Beverage | Cash or cash equivalent | ORENCIA Biological, Immunology | 2019 | |
| 2019-04-26 | E.R. Squibb & Sons, L.L.C. | $31 | Food and Beverage | Cash or cash equivalent | ORENCIA Biological, Immunology | 2019 | |
| 2019-04-26 | E.R. Squibb & Sons, L.L.C. | $31 | Food and Beverage | Cash or cash equivalent | ORENCIA Biological, Immunology | 2019 | |
| 2019-04-26 | E.R. Squibb & Sons, L.L.C. | $28 | Food and Beverage | Cash or cash equivalent | ORENCIA Biological, Immunology | 2019 | |
| 2019-04-25 | E.R. Squibb & Sons, L.L.C. | $494 | Travel and Lodging | Cash or cash equivalent | ORENCIA Biological, Immunology | 2019 | |
| 2019-04-25 | E.R. Squibb & Sons, L.L.C. | $188 | Travel and Lodging | Cash or cash equivalent | ORENCIA Biological, Immunology | 2019 | |
| 2019-04-25 | E.R. Squibb & Sons, L.L.C. | $125 | Food and Beverage | Cash or cash equivalent | ORENCIA Biological, Immunology | 2019 | |
| 2019-04-25 | E.R. Squibb & Sons, L.L.C. | $31 | Food and Beverage | Cash or cash equivalent | ORENCIA Biological, Immunology | 2019 | |
| 2019-04-25 | E.R. Squibb & Sons, L.L.C. | $23 | Travel and Lodging | Cash or cash equivalent | ORENCIA Biological, Immunology | 2019 | |
| 2019-04-04 | Janssen Biotech, Inc. | $14 | Food and Beverage | In-kind items and services | SIMPONI Biological, Immunology | 2019 | |
| 2019-04-04 | Janssen Biotech, Inc. | $5 | Food and Beverage | In-kind items and services | SIMPONI Biological, Immunology | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-09-29 | Eli Lilly and Company | ST PAUL RHEUMATOLOGY PA | $3,750 | A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-T | 2025 |
| 2025-09-03 | ABBVIE INC. | ST PAUL RHEUMATOLOGY PA | $615 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2025 |
| 2025-08-11 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $1,014 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2025 |
| 2025-06-02 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $2,163 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $399 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2025 |
| 2025-03-31 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $1,014 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2025 |
| 2025-03-17 | UCB SA | ST PAUL RHEUMATOLOGY PA | $44,924 | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-02-25 | Eli Lilly and Company | CLAYTON MEDICAL ASSOCIATES PC | $1,851 | A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-T | 2025 |
| 2025-01-31 | UCB SA | Saint Paul Rheumatology, Pa | $1,114 | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-01-27 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $1,537 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2025 |
| 2025-01-21 | E.R. Squibb & Sons, L.L.C. | Saint Paul Rheumatology, Pa | $49,329 | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) | 2025 |
| 2024-12-23 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $3,985 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2024 |
| 2024-11-25 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $399 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2024 |
| 2024-09-27 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $1,256 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2024 |
| 2024-09-02 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $1,803 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2024 |
| 2024-07-08 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $4,632 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2024 |
| 2024-06-07 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $1,389 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2024 |
| 2024-05-06 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $2,222 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2024 |
| 2024-04-01 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $1,956 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2024 |
| 2024-02-26 | E.R. Squibb & Sons, L.L.C. | Saint Paul Rheumatology, Pa | $9,171 | A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Ea | 2024 |
| 2024-02-05 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $4,234 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2024 |
| 2024-01-16 | E.R. Squibb & Sons, L.L.C. | Saint Paul Rheumatology, Pa | $199,725 | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjogrens | 2024 |
| 2023-12-31 | ABBVIE INC. | CENTRAL TEXAS NEUROLOGY CONSULTANTS | $1,056 | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2023 |
| 2023-12-15 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $4,426 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2023 |
| 2023-11-09 | E.R. Squibb & Sons, L.L.C. | Saint Paul Rheumatology, Pa | $2,834 | Phase III Sjogrens - A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety o | 2023 |
| 2023-11-08 | ABBVIE INC. | ST PAUL RHEUMATOLOGY PA | $9,000 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2023 |
| 2023-10-30 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $1,717 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2023 |
| 2023-09-29 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $10,221 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2023 |
| 2023-09-28 | E.R. Squibb & Sons, L.L.C. | Saint Paul Rheumatology, Pa | $17,959 | Phase III Sjogrens - A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety o | 2023 |
| 2023-07-27 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $14,115 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2023 |
| 2023-05-15 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $3,416 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2023 |
| 2023-03-07 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $2,337 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2023 |
| 2023-02-13 | Amgen Inc. | SAINT PAUL RHEUMATOLOGY PA | $12,240 | Ph4 Otezla in oligoarticular PsA (FOREMOST)/KEG | 2023 |
| 2023-02-03 | Janssen Research & Development, LLC | ST PAUL RHEUMATOLOGY PA | $5,090 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A | 2023 |
| 2023-01-21 | Amgen Inc. | ST PAUL RHEUMATOLOGY PA | $1,570 | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. (FOREMOST) | 2023 |
| 2023-01-05 | E.R. Squibb & Sons, L.L.C. | Saint Paul Rheumatology, Pa | $23,932 | AMPLIFIED Study - A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous | 2023 |
| 2022-12-31 | ABBVIE INC. | CENTRAL TEXAS NEUROLOGY CONSUL | $981 | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2022 |
| 2022-12-31 | ABBVIE INC. | ST PAUL RHEUMATOLOGY | $262 | A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis | 2022 |
| 2022-12-31 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2022 |
| 2022-11-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2022 |
| 2022-09-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2022 |
| 2022-08-31 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2022 |
| 2022-07-31 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2022 |
| 2022-06-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2022 |
| 2022-03-31 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2022 |
| 2022-02-28 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2022 |
| 2022-02-19 | Amgen Inc. | SAINT PAUL RHEUMATOLOGY PA | $9,118 | Ph4 Otezla in oligoarticular PsA (FOREMOST)/KEG | 2022 |
| 2022-02-08 | E.R. Squibb & Sons, L.L.C. | Saint Paul Rheumatology, Pa | $407 | AMPLIFIED Study - A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous | 2022 |
| 2022-01-31 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2022 |
| 2022-01-22 | Amgen Inc. | ST PAUL RHEUMATOLOGY PA | $8,461 | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis (FOREMOST) | 2022 |
| 2022-01-12 | Amgen Inc. | SAINT PAUL RHEUMATOLOGY PA | $150,457 | Ph4 Otezla in oligoarticular PsA (FOREMOST)/KEG | 2022 |
| 2021-12-31 | ABBVIE INC. | SAINT PAUL RHEUMATOLOGY PA | $524 | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult | 2021 |
| 2021-12-31 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-11-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-10-31 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-10-26 | E.R. Squibb & Sons, L.L.C. | Saint Paul Rheumatology, Pa | $91 | AMPLIFIED Study | 2021 |
| 2021-10-04 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $3 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-10-04 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $49 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-09-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-09-22 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $1,906 | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2021 |
| 2021-08-31 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-08-25 | Amgen Inc. | SAINT PAUL RHEUMATOLOGY PA | $27,697 | PSA-013/20200058 (KEG) (FOREMOST) | 2021 |
| 2021-08-23 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $1,906 | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2021 |
| 2021-07-31 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-07-21 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $2,034 | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2021 |
| 2021-07-12 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $215 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-06-23 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $2,034 | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2021 |
| 2021-06-01 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $50 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $159 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $28 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $63 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $2,597 | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $49 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $66 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $52 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $52 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $31 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $165 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $49 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $28 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $53 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-05-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | St. Paul Rheumatology | $206 | Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | 2021 |
| 2021-04-26 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $1,906 | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2021 |
| 2021-03-25 | Amgen Inc. | SAINT PAUL RHEUMATOLOGY PA | $258,286 | PSA-013/20200058 (KEG) (FOREMOST) | 2021 |
| 2021-03-17 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $408 | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2021 |
| 2021-03-17 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $816 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subje | 2021 |
| 2021-03-17 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $1,906 | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2021 |
| 2021-02-17 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $3,570 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subje | 2021 |
| 2021-02-17 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $1,906 | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2021 |
| 2021-02-17 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $2,362 | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2021 |
| 2021-01-20 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $5,914 | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2021 |
| 2020-12-23 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $1,869 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subje | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $3,926 | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2020 |
| 2020-12-11 | Amgen Inc. | SAINT PAUL RHEUMATOLOGY PA | $20,400 | Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) | 2020 |
| 2020-12-08 | E.R. Squibb & Sons, L.L.C. | Saint Paul Rheumatology, P A | $7,534 | PhIIIb Early Arthritis AVERT2 | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $2,016 | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $1,869 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subje | 2020 |
| 2020-10-23 | Amgen Inc. | ST PAUL RHEUMATOLOGY PA | $1,605 | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. (FOREMOST) | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $6,744 | A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filg | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | ST PAUL RHEUMATOLOGY PA | $1,906 | A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Eagan, MN, county Dakota County, MN, state Minnesota; placed by its city name.
| Measure | Place (city or town) Eagan, MN | County Dakota County, MN | State Minnesota |
|---|---|---|---|
| Population B01003 | 68,000 | 445,771 | 5,739,445 |
| Population, 2020 census P1 | 68,855 | 439,882 | 5,706,494 |
| Median age B01002 | 39.3 | 38.6 | 38.8 |
| Under 18 B01001 | 22.3% | 24.0% | 22.9% |
| 65 and over B01001 | 16.1% | 15.9% | 17.3% |
| Households B11001 | 28,264 | 174,362 | 2,307,955 |
| Foreign born B05002 | 14.9% | 10.1% | 8.7% |
| Median household income B19013 | $108,690 | $106,318 | $89,062 |
| Median family income B19113 | $139,022 | $131,618 | $113,993 |
| Per capita income B19301 | $57,112 | $52,084 | $48,237 |
| Poverty rate B17001 | 5.9% | 5.8% | 9.3% |
| Unemployment rate B23025 | 3.7% | 3.6% | 4.1% |
| Civilian labor force B23025 | 39,863 | 248,917 | 3,119,042 |
| Mean commute (minutes) B08013 | 21.2 | 23.6 | 22.7 |
| Bachelor's degree or higher B15003 | 54.7% | 45.0% | 39.4% |
| Housing units B25001 | 28,789 | 178,879 | 2,545,030 |
| Owner-occupied B25003 | 67.7% | 74.9% | 72.2% |
| Renters B25003 | 32.3% | 25.1% | 27.8% |
| Median home value B25077 | $397,100 | $381,000 | $329,300 |
| Median gross rent B25064 | $1,679 | $1,548 | $1,280 |
| White, not Hispanic B03002 | 68.4% | 72.7% | 75.9% |
| Black B03002 | 11.5% | 7.7% | 6.9% |
| Hispanic or Latino B03002 | 7.3% | 8.7% | 6.4% |
| Asian B03002 | 8.5% | 5.2% | 5.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.7% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Eagan, MN.
Comments